TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32889836

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (FFX)
Number of subjects: 413

Group type: COMPARATOR
Intervention: gemcitabine plus nab-paclitaxel (GNP)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: FFX-GNP crossover
Number of subjects: 413

Group type: COMPARATOR
Intervention: GNP-FFX crossover
Number of subjects: 413
Study: 35529283

Group type: EXPERIMENTAL
Intervention: Conventional acid-etch sealant (Group 1)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Self-etch sealant (Group 2)
Number of subjects: 35
Study: 33350893

Group type: EXPERIMENTAL
Intervention: Nonspherical polyvinyl alcohol (PVA) particles (355‐550 μm)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Tris‐acryl gelatin microspheres (TAGM) (500‐700 μm)
Number of subjects: 54
Study: 36273210

Group type: EXPERIMENTAL
Intervention: Strengthening exercises (group 1)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combination of strengthening exercises and functional swallowing therapy (group 2)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation added to the combination of strengthening exercises and functional swallowing therapy (group 3)
Number of subjects: 105
Study: 33205809

Group type: EXPERIMENTAL
Intervention: Ciraparantag (single IV dose at peak concentrations of the anticoagulant)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ciraparantag (given after the bleeding injury)
Number of subjects: 2
Study: 32151538

Group type: EXPERIMENTAL
Intervention: NELCIN-B3 protocol for managing early-detected lung nodules
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Routine CT protocol for managing early-detected lung nodules
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Quantitative measurement of CT imaging biomarkers
Number of subjects: 10000
Study: 32197070

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 35859298

Group type: EXPERIMENTAL
Intervention: Nano-silymarin (SinaLive soft gel, 70 mg silymarin as nanomicelles, three times daily for two weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (three times daily for two weeks)
Number of subjects: 50
Study: 34724938

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: Decision Tree model
Number of subjects: 2084

Group type: COMPARATOR
Intervention: GRACE risk variable set model
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: RBBB (Right Bundle Branch Block)
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: ≥ 2 ventricular walls motion abnormal
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: Right coronary artery occlusion
Number of subjects: 2084
Study: 35543652

Group type: EXPERIMENTAL
Intervention: Supraglottic airway device (SGA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bag-mask ventilation (BMV)
Number of subjects: 11
Study: 34166263

Group type: EXPERIMENTAL
Intervention: Early mobilization (self‐weaning from sling and performance of active range of motion as tolerated during first 6 weeks)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 101

Group type: COMPARATOR
Intervention: Immobilization (splinting for 6 weeks with no active range of motion)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Early mobilization and Immobilization
Number of subjects: 101
Study: 35534091

Group type: EXPERIMENTAL
Intervention: Vita 500 (liquid formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capsules
Number of subjects: 0
Study: 34342299

Group type: EXPERIMENTAL
Intervention: TREPP
Number of subjects: 0

Group type: COMPARATOR
Intervention: TIPP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TREPP (corrected for learning curve)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TIPP (corrected for learning curve)
Number of subjects: 0
Study: 36490244

Group type: EXPERIMENTAL
Intervention: Mobile health coaching via a mobile app for 3 months after discharge.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Face‐to‐face counseling with a clinical dietitian at 1 and 3 months postoperatively.
Number of subjects: 180
Study: 35519929

Group type: EXPERIMENTAL
Intervention: Helmet mask
Number of subjects: 60

Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 60
Study: 32804621

Group type: EXPERIMENTAL
Intervention: i‐PROACTIF intervention (Integrated PRimary care and Occupational therapy for Aging and Chronic disease Treatment to preserve Independence and Functioning)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: i‐PROACTIF intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Complex care management (control)
Number of subjects: 18
Study: 35377160

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl
Number of subjects: 1446

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1446
Study: 33488071

Group type: EXPERIMENTAL
Intervention: BDP/FF/G DPI (100/6/10µg via DPI, two inhalations twice daily for four weeks)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: BDP/FF/G pMDI (100/6/10µg via pMDI, two inhalations twice daily for four weeks)
Number of subjects: 366

Group type: COMPARATOR
Intervention: BDP/FF (100/6µg via pMDI, two inhalations twice daily for four weeks)
Number of subjects: 366
Study: 32394059

Group type: EXPERIMENTAL
Intervention: Pediatric surgical RCTs
Number of subjects: 0
Study: 34528079

Group type: EXPERIMENTAL
Intervention: secukinumab (300 or 150 mg weekly, then 4-weekly thereafter)
Number of subjects: 166

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: secukinumab
Number of subjects: 166
Study: 33408531

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose complex (ISC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low molecular weight iron dextran (LMWID)
Number of subjects: 40
Study: 34964475

Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia ablation
Number of subjects: 259

Group type: COMPARATOR
Intervention: Escalated antiarrhythmic drug therapy
Number of subjects: 259
Study: 33169168

Group type: EXPERIMENTAL
Intervention: Youth with stigmatizing attitudes towards patients with podoconiosis
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Accurate knowledge about gene-environment influences
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Rejection of infectious causes of podoconiosis
Number of subjects: 336
Study: 35846977

Group type: EXPERIMENTAL
Intervention: Smartphone application education (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional clinical education (n=30)
Number of subjects: 60
Study: 32564630

Group type: EXPERIMENTAL
Intervention: Self-compassion intervention (8 sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 24
Study: 36397018

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise (60 min per session, 3 sessions per week for 24 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual physical activity (control group)
Number of subjects: 72
Study: 35082913

Group type: EXPERIMENTAL
Intervention: DSA group
Number of subjects: 60

Group type: COMPARATOR
Intervention: CTA group
Number of subjects: 60
Study: 33020083

Group type: EXPERIMENTAL
Intervention: Cilostazol plus nimodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nimodipine alone
Number of subjects: 0
Study: 35313935

Group type: EXPERIMENTAL
Intervention: App-based intervention (HAPPYTEEN) based on Transtheoretical Model (TTM) and Cognitive-Behavioral Therapy (CBT) delivered over 8 sessions for 2 months
Number of subjects: 206

Group type: COMPARATOR
Intervention: Sleep hygiene intervention delivered over 8 sessions for 2 months via the app
Number of subjects: 206
Study: 33991702

Group type: EXPERIMENTAL
Intervention: Manipulative therapy of sacral torsion
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Myofascial release
Number of subjects: 64
Study: 32208117

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) transfersomal gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Free MB gel
Number of subjects: 30
Study: 35315874

Group type: EXPERIMENTAL
Intervention: Aspirin (n=565)
Number of subjects: 1557

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor (n=455)
Number of subjects: 1557

Group type: COMPARATOR
Intervention: No antiplatelet therapy (control; n=529)
Number of subjects: 1557
Study: 32439603

Group type: EXPERIMENTAL
Intervention: Imaginary eating of 30 colorful button-shaped chocolates (M&Ms)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Sorting of 30 M&Ms by color
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sorting of 30 marbles by color
Number of subjects: 86
Study: 35202073

Group type: EXPERIMENTAL
Intervention: Intervention program including three modules focusing on improving pharmacists’ communication skills to proactively offer naloxone.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group completing a reading assignment on the naloxone consensus guidelines.
Number of subjects: 0
Study: 32556176

Group type: EXPERIMENTAL
Intervention: Topical imiquimod cream followed by intradermal HBVv (IMQ + ID)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Topical aqueous cream (placebo) followed by intradermal HBVv (AQ + ID)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Topical aqueous cream followed by intramuscular HBVv (AQ + IM)
Number of subjects: 94
Study: 32338720

Group type: EXPERIMENTAL
Intervention: Cycled phototherapy (PT) regimen of 15 min/h or more
Number of subjects: 305

Group type: COMPARATOR
Intervention: Continuous phototherapy (PT)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Cycled phototherapy (PT)
Number of subjects: 305
Study: 33573341

Group type: EXPERIMENTAL
Intervention: iMBI plus treatment-as-usual
Number of subjects: 108

Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual
Number of subjects: 108
Study: 32238176

Group type: EXPERIMENTAL
Intervention: Guided self-help CBT intervention for voices (GiVE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive Counselling (SC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 35961614

Group type: EXPERIMENTAL
Intervention: Cooking Matters for Diabetes intervention (6-week program with weekly food provision of 4 servings)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cooking Matters for Diabetes intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Food insecure participants
Number of subjects: 48
Study: 33993525

Group type: EXPERIMENTAL
Intervention: Immediate postoperative use of epinephrine
Number of subjects: 5773

Group type: EXPERIMENTAL
Intervention: Immediate postoperative use of dobutamine
Number of subjects: 5773

Group type: EXPERIMENTAL
Intervention: Atrio-ventricular valve surgery
Number of subjects: 5773

Group type: COMPARATOR
Intervention: Hypertension
Number of subjects: 5773
Study: 35026880

Group type: EXPERIMENTAL
Intervention: Habb-e-Asab (250 mg twice a day for 45 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (250 mg twice a day for 45 days)
Number of subjects: 30
Study: 33289256

Group type: EXPERIMENTAL
Intervention: 24-month weight management programme
Number of subjects: 253

Group type: COMPARATOR
Intervention: Usual diabetes care (Control)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Ghrelin increase
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Ghrelin at 12 months
Number of subjects: 253
Study: 33961310

Group type: EXPERIMENTAL
Intervention: Domagrozumab 5 mg/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Domagrozumab 20 mg/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Domagrozumab 40 mg/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Domagrozumab (after switching from 5 mg/kg to 40 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 19
Study: 33180565

Group type: EXPERIMENTAL
Intervention: SIFT IT group treatment program (14-week duration)
Number of subjects: 2
Study: 36398695

Group type: EXPERIMENTAL
Intervention: Physiotherapy plus corticosteroid injection (combined), single injection 3-6 days before physiotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 50
Study: 34691078

Group type: EXPERIMENTAL
Intervention: N501Y mutation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E484K mutation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined P.1 and B.1.351 RBD variants
Number of subjects: 0
Study: 36384815

Group type: EXPERIMENTAL
Intervention: Health Belief Model (HBM)‐based mobile messaging to adolescents and their parents for 24 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Health Belief Model (HBM)‐based messaging to adolescents only for 24 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Delivering e‐version of oral health education pamphlets to adolescents
Number of subjects: 12
Study: 32197829

Group type: EXPERIMENTAL
Intervention: 3.5 mm anterior locking plate (LP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cannulated screws with anterior tension band wiring (hybrid osteosynthesis, HO)
Number of subjects: 16
Study: 33346579

Group type: EXPERIMENTAL
Intervention: DGP-IgG
Number of subjects: 133

Group type: COMPARATOR
Intervention: TTG-IgA
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: DGP-IgG added to TTG-IgA
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: DGP-IgG titer >2 times ULN
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: DGP-IgG titer >4 times ULN
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: TTG-IgA >10 times ULN in T1D patients
Number of subjects: 133
Study: 32877578

Group type: EXPERIMENTAL
Intervention: IONIS-PKK-LRx administered at a dose of 80 mg every 3 to 4 weeks for 7 to 8 months after initial treatment with IONIS-PKKRx for 12 to 16 weeks.
Number of subjects: 2

Group type: COMPARATOR
Intervention: IONIS-PKKRx administered weekly subcutaneous injections for 12 to 16 weeks.
Number of subjects: 2
Study: 34979585

Group type: EXPERIMENTAL
Intervention: Tourniquet inflated from skin incision to cement hardening
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tourniquet from cement application to hardening
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tourniquet from skin incision to skin closure
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 90
Study: 33176129

Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) system at 2 kg/L/minute, up to a maximum of 30 L/minute
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nasal cannula (NC) group at 5 L/minute
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) system
Number of subjects: 30
Study: 32459987

Group type: EXPERIMENTAL
Intervention: Memory Support Intervention with multiple types of memory support strategies
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Memory Support Intervention with one type of memory support strategy
Number of subjects: 428

Group type: COMPARATOR
Intervention: Control intervention (no memory support)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Memory and learning of treatment contents
Number of subjects: 428
Study: 35367003

Group type: EXPERIMENTAL
Intervention: ZyCoV-D vaccine (2 mg per dose, 3 doses administered intradermally via a needle-free injection system 28 days apart)
Number of subjects: 27703

Group type: COMPARATOR
Intervention: Placebo (3 doses administered intradermally via a needle-free injection system 28 days apart)
Number of subjects: 27703

Group type: EXPERIMENTAL
Intervention: ZyCoV-D vaccine
Number of subjects: 27703

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27703
Study: 34783725

Group type: EXPERIMENTAL
Intervention: Gabapentin 600mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paracetamol 1000mg
Number of subjects: 50
Study: 32066412

Group type: EXPERIMENTAL
Intervention: Microbiota-directed complementary food formulation (MDCF-2)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Conventional Ready-to-use Supplementary Food (RUSF)
Number of subjects: 248
Study: 35565844

Group type: EXPERIMENTAL
Intervention: SAx (oral supplement containing Hydroxytyrosol and Punicalagin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34863109

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1 μg/kg/hour)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 34272791

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4742
Study: 32725779

Group type: EXPERIMENTAL
Intervention: Image-guided radiotherapy (IGRT)
Number of subjects: 797

Group type: COMPARATOR
Intervention: Non-image-guided radiotherapy (non-IGRT)
Number of subjects: 797
Study: 36153600

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group (no POCUS)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: POCUS
Number of subjects: 244
Study: 33323224

Group type: EXPERIMENTAL
Intervention: Coach-supported internet intervention for self-management
Number of subjects: 2724

Group type: COMPARATOR
Intervention: Control platform
Number of subjects: 2724
Study: 35079831

Group type: EXPERIMENTAL
Intervention: Manual lymph drainage (MLD) with progressive arm exercises; n=48
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard arm exercises; n=48
Number of subjects: 96
Study: 34367287

Group type: EXPERIMENTAL
Intervention: Autogenous bone mixed with bioactive glass (1:1 in volume)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autogenous bone alone
Number of subjects: 0
Study: 36383828

Group type: EXPERIMENTAL
Intervention: Co-debriefing (intervention, n=9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Debriefing with a facilitator (control, n=8)
Number of subjects: 17
Study: 32929646

Group type: EXPERIMENTAL
Intervention: CSF Aβ42
Number of subjects: 314278

Group type: EXPERIMENTAL
Intervention: Plasma amyloid species
Number of subjects: 314278

Group type: EXPERIMENTAL
Intervention: CSF total tau
Number of subjects: 314278

Group type: EXPERIMENTAL
Intervention: Phosphorylated tau181
Number of subjects: 314278

Group type: EXPERIMENTAL
Intervention: Higher genetically predicted plasma amyloid species, CSF total tau and phosphorylated tau181
Number of subjects: 314278
Study: 32727496

Group type: COMPARATOR
Intervention: Intravitreal injections of ranibizumab (0.5 mg) alone (IVOM-Group)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravitreal injections of ranibizumab (0.5 mg) with additional micropulse diode laser (IVOM+Laser-Group)
Number of subjects: 19
Study: 34596747

Group type: EXPERIMENTAL
Intervention: HUMI + (humidified warm gas with forced air warming blanket)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HUMI (humidified warm gas without forced air warming blanket)
Number of subjects: 150

Group type: COMPARATOR
Intervention: AIR (dry cold CO2 with forced air warming blanket)
Number of subjects: 150
Study: 32803005

Group type: EXPERIMENTAL
Intervention: Integrated health promotion intervention (two sessions of 45 to 60 minutes Psychoeducational counseling, four telephone follow‐up support, and training pamphlets)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine education (Control group)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Integrated health promotion intervention
Number of subjects: 130
Study: 35037597

Group type: EXPERIMENTAL
Intervention: Atorvastatin with nortriptyline
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo with nortriptyline
Number of subjects: 68
Study: 34517869

Group type: EXPERIMENTAL
Intervention: Cogmed cognitive training (25 sessions over 5 to 8 weeks)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard care management (control group)
Number of subjects: 166
Study: 32580074

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (ECV)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Maintenance of sinus rhythm (SR)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: AF relapse after successful ECV
Number of subjects: 148
Study: 36413388

Group type: EXPERIMENTAL
Intervention: DiSCoVR (VR-SCT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: VRelax (active control)
Number of subjects: 81
Study: 32900520

Group type: EXPERIMENTAL
Intervention: Stearic acid diet
Number of subjects: 34
Study: 32085906

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI) to achieve/maintain 7% weight loss
Number of subjects: 5125

Group type: COMPARATOR
Intervention: Standard Diabetes Support and Education (DSE)
Number of subjects: 5125
Study: 33793972

Group type: EXPERIMENTAL
Intervention: Exercise test to exhaustion for cardiorespiratory fitness (CRF) assessment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Accelerometer (Actigraph GT3X+) for estimating physical activity (PA)
Number of subjects: 37
Study: 32361977

Group type: EXPERIMENTAL
Intervention: IMU‐838 (vidofludimus calcium) single doses (10-40 mg fasting, 10 mg fed)
Number of subjects: 64

Group type: COMPARATOR
Intervention: IMU‐838 (vidofludimus calcium) multiple doses (30-50 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (in MAD study)
Number of subjects: 64
Study: 33820455

Group type: EXPERIMENTAL
Intervention: Intermittent aerobic exercise (cycling at 70% peak Watts)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 12
Study: 33542279

Group type: EXPERIMENTAL
Intervention: 3‐nitrooxypropanol (3‐NOP), administered daily from birth until three weeks post‐weaning (week 14)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 18
Study: 32463430

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (ATE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Watchful Waiting
Number of subjects: 60
Study: 35124707

Group type: EXPERIMENTAL
Intervention: P-PRP
Number of subjects: 610

Group type: COMPARATOR
Intervention: Sham saline
Number of subjects: 610
Study: 33775526

Group type: EXPERIMENTAL
Intervention: HOT conditions (∼50 °C, ∼35% relative humidity) at Tre of 39.5 °C
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HOT conditions (∼50 °C, ∼35% relative humidity) at Tre of 38.5 °C and 39.5 °C
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HOT conditions (∼50 °C, ∼35% relative humidity)
Number of subjects: 9

Group type: COMPARATOR
Intervention: CON conditions (∼22 °C, ∼35% relative humidity) at Tre of ∼37 °C
Number of subjects: 9